Stock ICAD ICAD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

iCAD, Inc. Stock

Equities

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.56 USD +2.63% Intraday chart for iCAD, Inc. -2.50% -11.86%
Apr. 11 ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium CI
Apr. 09 ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation CI

Financials (USD)

Sales 2024 * 18.51M Sales 2025 * 23.51M Capitalization 41.11M
Net income 2024 * -6M Net income 2025 * -4M EV / Sales 2024 * 2.22 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.75 x
P/E ratio 2024 *
-6.69 x
P/E ratio 2025 *
-8.43 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.53%
More Fundamentals * Assessed data

Chart iCAD, Inc.

Dynamic Chart

Latest news about iCAD, Inc.

ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium CI
ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation CI
ICAD, Inc. Announces Commercial Availability of ProFound Cloud CI
Transcript : ICAD, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (ICAD) ICAD Posts Q4 Revenue $4.7M, vs. Street Est of $4.3M MT
ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
ICad to Present Three Mammography Studies at Radiology Conference; Shares Rise MT
ICAD, Inc. Appoints Hedvig Hricak to the Board of Directors CI
ICAD, Inc. Appoints Michael John Doyle to its Board of Directors CI
Icade Appoints New CFO MT
ICAD, Inc. Expands Executive Sales Leadership Team as Business Grows CI
ICAD, Inc. AI-Powered Solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare CI
ICAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite CI
Icade Closes Divestment of Grand Central Building in France MT
ICAD Partners With CancerIQ to Expand Breast Healthcare Service MT
More news

Latest transcript on iCAD, Inc.

Logo iCAD, Inc.
ICAD, Inc., Q4 2023 Earnings Call, Mar 12, 2024
More transcripts

Analyst Recommendations on iCAD, Inc.

Lake Street Adjusts Price Target on icad to $5 From $2.50, Maintains Buy Rating MT
JMP Securities Adjusts iCAD's Price Target to $4 From $7, Keeps Outperform Rating MT
Oppenheimer Adjusts iCAD Price Target to $4 From $5, Maintains Outperform Rating MT
JMP Securities Adjusts icad's Price Target to $7 From $13, Maintains Market Outperform Rating MT
Lake Street Adjusts icad Price Target to $8 From $13, Maintains Buy Rating MT
More recommendations

Press releases iCAD, Inc.

ICAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium AQ
ICAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation AQ
ICAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting AQ
ICAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs) AQ
ICAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale AQ
More press releases

News in other languages on iCAD, Inc.

LA PREMIÈRE ÉTAPE DE L’OPÉRATION CONSISTE EN LA CESSION PAR ICAD…
CAC 40 : Les valeurs à suivre à Paris et en Europe
ICAD : annonce l’installation de la solution ProFound AI™ 2D pour la mammographie et pour la tomosynthèse (DBT) 3D au Centre d’Imagerie Paris Nord Sarcelles
Dow Jones Industrial Average : Wall Street attendue en hausse malgré Intel et les doutes sur la croissance
CAC 40 : Les valeurs à suivre à Paris et en Europe
More news

Quotes and Performance

1 day+2.63%
1 week-2.50%
Current month-3.11%
1 month-2.50%
3 months+1.30%
6 months+2.63%
Current year-11.86%
More quotes

Highs and lows

1 week
1.45
Extreme 1.45
1.62
1 month
1.45
Extreme 1.45
1.99
Current year
1.25
Extreme 1.25
2.65
1 year
1.05
Extreme 1.05
3.97
3 years
1.05
Extreme 1.05
19.00
5 years
1.05
Extreme 1.05
21.44
10 years
1.05
Extreme 1.05
21.44
More quotes

Managers and Directors - iCAD, Inc.

Managers TitleAgeSince
Dana Brown CEO
 Chief Executive Officer 59 22-01-09
Eric Lonnqvist DFI
 Director of Finance/CFO 49 21-01-31
Michelle Strong COO
 Chief Operating Officer - 23-04-30
Members of the board TitleAgeSince
Dana Brown CEO
 Chief Executive Officer 59 22-01-09
Andrew Sassine BRD
 Director/Board Member 59 15-12-08
Susan Wood BRD
 Director/Board Member 60 18-09-25
More insiders

Quotes

Date Price Change Volume
24-04-23 1.56 +2.63% 101,101
24-04-22 1.52 -1.30% 190,961
24-04-19 1.54 -3.14% 67,632
24-04-18 1.59 +1.92% 143,093
24-04-17 1.56 -2.50% 86,761

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes

Company Profile

iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-05-07 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for iCAD, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.56 USD
Average target price
4.833 USD
Spread / Average Target
+209.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
ICAD, INC. Stock iCAD, Inc.
-11.86% 41.11M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.35% 219B
DANAHER CORPORATION Stock Danaher Corporation
+9.41% 187B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.75% 134B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+19.34% 101B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.76% 62.27B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+15.08% 52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-2.10% 47.49B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+0.10% 40.79B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.50% 39.35B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. ICAD Stock